Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
In 2006, Anderson joined Genentech, where he eventually became the senior vice president of the immunology, ophthalmology and bio-oncology divisions. [9] In 2013, Anderson moved to Switzerland to be head of global product strategy and chief marketing officer of the pharmaceuticals division at the Roche Holding AG. [9]
The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine in February 2013, and granted the application for Kadcyla to Genentech. [18] The FDA granted the application for trastuzumab emtansine priority review and breakthrough therapy designations. [24] In 2013, trastuzumab emtansine was approved in the UK, [4] and the EU. [6]
Trastuzumab emtansine (ado-trastuzumab emtansine or T-DM1, trade name: Kadcyla, marketed by Genentech and Roche) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who had received prior treatment with trastuzumab and a taxane chemotherapy. [13] [14]
oncology: Opdivo 7570 5763 6 pembrolizumab: oncology: Keytruda 7171 3809 7 etanercept: rheumatoid arthritis: Enbrel 7126 7885 8 trastuzumab: breast cancer: Herceptin 6981 7013 9 bevacizumab: colon cancer: Avastin 6847 6686 10 rituximab: non-Hodgkin's lymphoma: Rituxan, MabThera 6750 7298 11 rivaroxaban: anticoagulant: Xarelto 6589 6234 12 ...
The FDA granted the application of polatuzumab vedotin breakthrough therapy, priority review, and orphan drug designations. [9] The FDA granted the approval of Polivy to Genentech. [9] Polatuzumab vedotin was approved for medical use in the European Union in January 2020, as a second-line treatment. [7]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more